<unk>  is a kinase inhibitor that is FDA approved for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy.   Common adverse reactions include diarrhea, nausea, abdominal pain, fatigue, vomiting, rash, stomatitis, decreased appetite, muscle spasms, dyspepsia, AST or ALT increase, nail disorder, dry skin, abdominal distention, weight decreased and urinary tract infection.
Neratinib
Fostamatinib
Dasatinib
Afatinib
Lenvatinib
Brigatinib
Lorlatinib
Dabrafenib mesylate